Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies

Drugs of Today

Volumn 32, Issue 5, 1996, Pages 417-421

  Mehta, Jayesh ^a   Chu, Patrick ^b   Powles, Ray ^a   Kelsey, Steve ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID;

ADOLESCENT; ADULT; AGED; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CHEMOTHERAPY; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; FEVER; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; REVIEW; TACHYCARDIA;

EID: 0029833431     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1996.32.5.379051     Document Type: Review

References (13)

1. Rubin, R.H., Ferraro, M.J. Understanding and diagnosing infectious complications in the immunocompromised host: Current issues and trends. Hematol Oncol Clin North Amer 1993, 7: 795-812.
2. Goodrich, J.M., Reed, E.C., Mori, M. et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991, 164: 731-40.
3. Morrison, V.A., Haake, R.J., Weisdorf, D.J. The spectrum of non-Candida fungal infections following bone marrow transplantation. Med Baltimore 1993, 72: 78-89.
4. Pizzo, P.A. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993, 328: 1323-32.
5. Bowler, W.A., Oldfield, E.C. New approaches to amphotericin B administration. Infect Med 1992, 9: 17-23.
6. Carr, M., Dismukes, W.E. Antifungal drugs. In: Infectious Diseases. Gorbach, J.L., Bartlett, J.G., Blacklow, N.R. (Eds.). WB Saunders: Philadelphia 1992, 306-13.
7. Pizzo, P.A., Meyers, J., Freifeld, A.G., Walsh, T. Infections in the cancer patient. In: Cancer: Principles & Practice of Oncology, 4th Ed. De Vita, V.T., Hellman, S., Rosenberg, S.A. (Eds.). Lippincott: Philadelphia 1993, 2292-333.
8. Janoff, A.S., Perkins, W.R., Saleton, S.L., Swenson, C.E. Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993, 3: 451-72.
9. Mehta, J., Kelsey, S.M., Chu, P. et al. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. Blood 1995, 86 (Suppl. 1): Abst 2042.
10. Mehta, J., Chu, P., Powles, R. et al. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. Bone Marrow Transplant 1996, 17 (Suppl. 1): S64.
11. Hiemenz, J.W., Lister, J., Anaissie, E.J. et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical control comparison with amphotericin B. Blood 1995, 86 (Suppl. 1): Abst 3383.
12. Anaissie, E.J., White, M., Uzun, O. et al. Amphotericin B lipid complex (ABLC) vs amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst LM21.
13. Walsh, T.J., Hiemenz, J.W.,Seibel, N., Anaissie, E.J. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst M69.